Form 8-K

8-K — Cigna Group

Accession: 0001140361-26-030135

Filed: 2026-07-30

Period: 2026-07-30

CIK: 0001739940

SIC: 6324 (HOSPITAL & MEDICAL SERVICE PLANS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — ef20078875_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (ef20078875_ex99-1.htm)

GRAPHIC (image00001.jpg)

GRAPHIC (image00002.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ef20078875_8k.htm · Sequence: 1

false0001739940NYSE00017399402026-07-302026-07-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 30, 2026

The Cigna Group

(Exact name of registrant as specified in its charter)

Delaware

001-38769

82-4991898

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

900 Cottage Grove Road

Bloomfield, Connecticut 06002

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (860) 226-6000

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the

following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $0.01

New York Stock Exchange, Inc.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule

12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or

revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition.

On July 30, 2026, The Cigna Group issued a press release announcing results for the three months ended June 30, 2026. The press release is furnished as

Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or

incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act whether made before or after the date of this Current Report on Form 8-K, except as expressly set forth by specific reference in such a filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press release dated July 30, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the

undersigned hereunto duly authorized.

THE CIGNA GROUP

Date: July 30, 2026

By:

/s/ Ann M. Dennison

Ann M. Dennison

Executive Vice President and Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: ef20078875_ex99-1.htm · Sequence: 2

Exhibit 99.1

INVESTOR RELATIONS CONTACT:

Ralph Giacobbe

860-787-7968

Ralph.Giacobbe@TheCignaGroup.com

MEDIA CONTACT:

Justine Sessions

860-810-6523

Justine.Sessions@Evernorth.com

The Cigna Group Reports Strong Second Quarter 2026 Results, Raises 2026 Outlook

•

Total revenues for the second quarter 2026 increased 7% to $71.7 billion

•

Shareholders’ net income for the second quarter 2026 was $1.7 billion, or $6.29 per share

•

Adjusted income from operations1 for the second quarter 2026 was $2.1 billion, or $7.78 per share

•

2026 outlook2 for adjusted income from operations1,2 increased to at least $30.45 per share2

BLOOMFIELD, CT, July 30, 2026 – Global health company The Cigna Group (NYSE: CI) today reported second quarter 2026 results, reflecting solid operational performance across its diversified portfolio of businesses.

“Our purpose is to improve the lives of each and every customer and patient we serve,” said Brian C. Evanko, President and Chief Executive Officer of The Cigna Group. “By

harnessing technology, data and AI to deliver more personalized experiences, improve access and lower costs, we are creating greater value every day. Our strong second quarter results reflect continued progress against these priorities and

demonstrate the effectiveness of our strategy and execution.”

Shareholders’ net income for second quarter 2026 was $1.7 billion, or $6.29 per share compared to $1.5 billion, or $5.71 per share, for second

quarter 2025, primarily reflecting growth in Cigna Healthcare.

The Cigna Group’s adjusted income from operations1 for second quarter 2026 was $2.1 billion, or $7.78

per share, compared with $1.9 billion, or $7.20 per share, for second quarter 2025.

A reconciliation of shareholders’ net income to adjusted income from operations1 is provided on the following page and on Exhibit 1 of

this earnings release.

CONSOLIDATED HIGHLIGHTS

The following table includes highlights of results and reconciliations of

total revenues to adjusted revenues3 and shareholders’ net income to adjusted income from operations1:

Consolidated Financial Results (unaudited, dollars in millions):

Three Months Ended

Six Months

Ended

June 30,

March 31,

June 30,

2026

2025

2026

Total Revenues

71,668

67,178

68,494

140,162

Net Investment Results from Equity Method Investments3

(110

)

(44

)

(87

)

Adjusted Revenues3

71,558

67,134

68,517

140,075

Consolidated Earnings, net of taxes

Shareholders’ Net Income

1,660

1,532

1,654

3,314

Net Investment (Gains)1

(55

)

(103

)

(233

)

(288

)

Amortization of Acquired Intangible Assets1

296

330

315

611

Special Items1

153

171

322

475

Adjusted Income from Operations1

2,054

1,930

2,058

4,112

Shareholders’ Net Income, per share

6.29

5.71

6.26

12.55

Adjusted Income from Operations1, per share

7.78

7.20

7.79

15.58

•

Total revenues for second quarter 2026 increased

7% relative to second quarter 2025, driven by growth in both Evernorth Health Services and Cigna Healthcare.

•

Adjusted income from operations1 for second quarter 2026 increased 6% relative to second quarter 2025, driven by higher contributions from Cigna Healthcare.

•

The SG&A expense ratio4 and adjusted SG&A expense ratio4 were 4.8% and 4.6% for second quarter 2026,

compared to 5.1% and 4.9%, respectively, in second quarter 2025, primarily reflecting operating efficiency.

•

Year to date through July 29, 2026, the company repurchased 0.9 million shares of common stock for approximately $250 million.

CUSTOMER RELATIONSHIPS

The following table summarizes The Cigna Group’s medical customers and overall customer relationships:

Customer Relationships (in thousands):

As of the Periods Ended

June 30,

March 31,

December 31,

2026

2025

2026

2025

Total Pharmacy Customers

118,243

121,892

121,020

123,603

U.S. Healthcare

16,678

16,355

16,623

16,423

International Health

1,735

1,691

1,711

1,695

Total Medical Customers5

18,413

18,046

18,334

18,118

Behavioral Care

27,621

23,852

27,558

28,269

Dental

18,488

18,446

18,558

18,438

Total Customer Relationships

182,765

182,236

185,470

188,428

•

Total customer relationships at June 30, 2026 decreased 3% from December 31, 2025 to 182.8 million.

•

Total pharmacy customers at June 30, 2026 decreased 4%

from December 31, 2025 to 118.2 million, reflecting expected client transitions and lower membership from health plan clients.

•

Total medical customers5 at June 30, 2026 increased 2% from December 31, 2025 to 18.4 million reflecting

growth in Middle and Select markets, partially offset by lower membership in National Accounts.

HIGHLIGHTS OF SEGMENT RESULTS

See Exhibit 1 for a reconciliation of adjusted income from operations1 to shareholders’ net income.

Evernorth Health Services

This segment includes the Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and

capabilities to enable the health care system to work better and help people live healthier lives.

Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services such as drug claim adjudication, retail pharmacy network

administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty

distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services.

Financial Results (dollars in millions):

Three Months Ended

Six Months

Ended

June 30,

March 31,

June 30,

2026

2025

2026

Total Adjusted Revenues

Pharmacy Benefit Services

34,496

31,954

33,002

67,498

Specialty and Care Services

26,972

25,871

25,440

52,412

Adjusted Revenues3

61,468

57,825

58,442

119,910

Adjusted Income from Operations, Pre-Tax

Pharmacy Benefit Services

609

833

394

1,003

Specialty and Care Services

1,054

863

1,072

2,126

Adjusted Income from Operations, Pre-Tax1

1,663

1,696

1,466

3,129

Margin, Pre-Tax6

2.7

2.9

2.5

2.6

•

Evernorth Health Services second quarter 2026

adjusted revenues3 increased 6% and adjusted income from operations, pre-tax1, decreased 2%, relative to second quarter 2025.

•

For Pharmacy Benefit Services second quarter 2026

relative to second quarter 2025:

◦

Adjusted revenues3 increased 8% primarily due to drug mix.

◦

Adjusted income from operations, pre-tax1, decreased 27%, primarily reflecting client-focused initiatives, including large client contract renewals, and customer-focused initiatives, consistent with prior commentary.

•

For Specialty and Care Services second quarter 2026

relative to second quarter 2025:

◦

Adjusted revenues3 increased 4% reflecting strong specialty volume growth.

◦

Adjusted income from operations, pre-tax1, increased 22% primarily reflecting strong organic growth in specialty

businesses, including higher generic and biosimilar adoption which benefits clients and patients by delivering lower costs, and operating efficiencies.

Cigna Healthcare

This segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and

customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured and self-insured clients as well as individual and family plan customers.

International Health provides health care solutions in our international markets, as well as health solutions for globally mobile individuals and employees of multinational organizations. In April 2026, the Company announced its planned exit from the Individual and Family Plans medical business as of January 1, 2027.

Financial Results (dollars in millions):

Three Months Ended

Six Months

Ended

June 30,

March 31,

June 30,

2026

2025

2026

Adjusted Revenues3,7

11,728

10,754

11,477

23,205

Adjusted Income from Operations, Pre-Tax1

1,276

1,094

1,514

2,790

Margin, Pre-Tax6

10.9

10.2

13.2

12.0

•

Second quarter 2026 adjusted revenues3 increased 9% relative to second

quarter 2025, primarily reflecting premium rate increases to cover expected increases in medical costs.

•

Second quarter 2026 adjusted income from operations, pre-tax1, increased 17% relative to second quarter 2025, primarily due to an improved margin within our U.S. Employer business.

•

The Cigna Healthcare MCR4 was 84.5% for second

quarter 2026, compared to 83.2% for second quarter 2025, primarily reflecting higher prior year risk adjustment benefits within our Individual and Family Plans business recognized in second quarter 2025.

•

Cigna Healthcare net medical costs payable8 was $5.09 billion at June 30, 2026, $4.78 billion at March 31, 2026, and $4.49 billion at June 30, 2025. The sequential increase reflects typical stop loss seasonality. Favorable prior year reserve development on a gross pre-tax basis was $268 million and $297 million for the six months ended June 30, 2026 and 2025, respectively.

Corporate and Other Operations

Corporate reflects interest expense, amounts not

allocated to operating segments and includes intersegment eliminations. Other Operations is comprised of Corporate Owned Life Insurance (“COLI”), the Company’s run-off operations and other non-strategic businesses.

Financial Results (dollars in millions):

Three Months Ended

Six Months

Ended

June 30,

March 31,

June 30,

2026

2025

2026

Adjusted (Loss) from Operations, Pre-Tax1

(389

)

(357

)

(377

)

(766

)

2026 OUTLOOK2

The Cigna Group’s outlook for full year 2026 consolidated adjusted income from operations1,2

is at least $30.45 per share2. Additionally, this outlook includes the impact of expected future share repurchases and anticipated 2026 dividends.

(dollars in millions, except where noted and per share amounts)

2026 Consolidated Metrics

Projection for Full Year Ending

December 31, 2026

Change from

Prior Projection

Adjusted Income from Operations, per share1,2

at least $30.45

+$0.10

Evernorth Adjusted Income from Operations, Pre-Tax1,2

at least $6,900

Cigna Healthcare Adjusted Income from Operations, Pre-Tax1,2

at least $4,550

+$25

Cigna Healthcare Medical Care Ratio2,4

83.7% to 84.7%

The foregoing statements represent the Company’s current estimates of The Cigna Group’s 2026 consolidated and segment adjusted income from operations1,2 and other key metrics as of the date of this release. Actual results may differ materially depending on a number of factors.

Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates.

This quarterly earnings release and the Quarterly Financial Supplement are available on The Cigna Group’s website in the Investor Relations section (https://investors.thecignagroup.com/overview/default.aspx). Management will be hosting a conference call to review second

quarter 2026 results and discuss full year 2026 outlook beginning today at 8:30 a.m. ET. A

link to the conference call is available in the Investor Relations section of The Cigna Group’s website located at https://investors.thecignagroup.com/events-and-presentations/default.aspx.

The call-in numbers for the conference call are as follows:

Live Call

(888) 566-1889 (Domestic)

(773) 799-3989 (International)

Passcode: 07302026

Replay

(866) 405-7290 (Domestic)

(203) 369-0603 (International)

It is strongly suggested you dial in to the conference call by 8:15 a.m. ET.

About The Cigna Group

The Cigna Group (NYSE: CI) is a global health company committed to creating a better

future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Evernorth Health Services,

Cigna Healthcare, or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 markets and jurisdictions, and has over 180 million customer relationships around the world. Learn more at thecignagroup.com.

Notes:

Adjusted income (loss) from operations is a principal financial measure of profitability used by The Cigna Group’s management because it presents the

underlying results of operations of the Company’s businesses and facilitates analysis of trends in underlying revenue, expenses and shareholders’ net income. Adjusted income (loss) from operations is defined as shareholders’ net income (or

income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group’s

share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the

underlying results of normal, recurring operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. Consolidated

adjusted income (loss) from operations is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, shareholders’ net income. See Exhibit 1 for a reconciliation of

consolidated adjusted income from operations to shareholders’ net income.

Management is not able to provide a reconciliation of adjusted income from operations to shareholders’ net income, on a forward-looking basis because it is unable to predict,

without unreasonable effort, certain components thereof including (i) future net investment results and (ii) future special items. These items are inherently uncertain and depend on various factors, many of which are beyond The Cigna Group’s

control. As such, any associated estimate and its impact on shareholders’ net income and total revenues could vary materially.

The Company’s outlook excludes the potential

effects of any other business combinations that may occur after the date of this earnings release. The Company’s outlook includes the potential effects of expected future share repurchases and anticipated 2026 dividends.

The timing and actual number of shares repurchased will depend on a variety of factors, including price,

general business and market conditions, and alternate uses of capital. The share repurchase program may be effected through open market purchases in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, including through

Rule 10b5-1 trading plans, or privately negotiated transactions. The program may be suspended or discontinued at any time.

Adjusted revenues is used by The Cigna Group’s management because it facilitates analysis of trends in underlying revenue. The Company defines adjusted revenues as total revenues

excluding the following adjustments: special items and The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that

management believes are not representative of the underlying results of normal, recurring operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future

underlying performance of the business. Adjusted revenues is not determined in accordance with GAAP and should not be viewed as a substitute for the most directly comparable GAAP measure, total revenues. See Exhibit 1 for a reconciliation of

consolidated adjusted revenues to total revenues.

Operating ratios are defined as follows:

•

The Cigna Healthcare medical care ratio (“MCR”) represents medical costs as a percentage of premiums for all Cigna Healthcare risk products provided through guaranteed cost or

experience-rated funding arrangements. Changes in percentages may be expressed in basis points (“bps”).

•

SG&A expense ratio on a GAAP basis for the second quarter 2026 represents enterprise selling, general and administrative expenses of $3,470 million as a percentage of total revenue of $71.7 billion at a consolidated level. SG&A expense ratio on a GAAP basis for the second

quarter 2025 represents enterprise selling, general and administrative expenses of $3,433 million

as a percentage of total revenue of $67.2 billion at a consolidated level.

•

Adjusted SG&A expense ratio for the second quarter 2026 represents enterprise selling, general and administrative expenses of $3,290 million excluding special items of $180 million as a percentage of adjusted revenue at a consolidated level. Adjusted SG&A expense ratio for the second quarter 2025 represents enterprise selling, general and administrative expenses of $3,271 million excluding special items of $162 million as a percentage of adjusted revenue at a consolidated level.

Customer relationships are defined as follows:

•

Total medical customers includes individuals who meet any one of the following criteria: (i) are covered under a medical insurance policy, managed care

arrangement, or administrative services agreement issued by Cigna Healthcare; (ii) have access to Cigna Healthcare’s provider network for covered services under their medical plan; or (iii) have medical claims that are administered by Cigna

Healthcare.

Margin, pre-tax, is calculated by dividing adjusted income (loss) from operations, pre-tax by adjusted revenues for each segment.

The Cigna Group owns noncontrolling interests in certain operating joint ventures. As such, the adjusted revenues for the Cigna Healthcare segment only include the Company’s share

of the joint ventures’ earnings reported in Fees and Other Revenues using the equity method of accounting under GAAP.

Medical costs payable within the Cigna Healthcare segment are presented net of reinsurance and other

recoverables. The gross medical costs payable balance was $5.23 billion as of June 30, 2026,

$4.92 billion as of March 31, 2026, and $4.64 billion as of June 30, 2025.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release, and oral statements made in connection with this release, may contain forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group’s current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may

include, among others, statements concerning our projected outlook for 2026 (including adjusted

revenues; adjusted income from operations, including on a per share, and segment basis; adjusted SG&A expense ratio; adjusted effective tax rate; cash flow from operations; capital expenditures; shareholder dividends; weighted average shares

outstanding; medical care ratio; and total medical customers); future financial or operating performance, including our ability to improve the health and vitality of those we serve; future growth, business strategy and strategic or operational

initiatives, including our ability to successfully implement actions across our business to strengthen our platform and build a more sustainable model for healthcare; economic, regulatory or competitive environments; capital deployment plans and

amounts available for future deployment; our prospects for growth in the coming years; and other statements regarding The Cigna Group’s future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You

may identify forward-looking statements by the use of words such as “believe,” “expect,” “project,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “may,” “should,” “will” or other words or expressions of similar meaning, although

not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or

implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to manage health care costs and respond to price competition, inflation and other pressures that could compress our margins or result in

premiums that are insufficient to cover the cost of services delivered to our customers; our ability to compete effectively, differentiate our products and services from those of our competitors and adapt to changes in an evolving and rapidly

changing industry; our ability to develop and effectively implement products and services to improve the accessibility, affordability and transparency of health care; changes in drug pricing or industry pricing benchmarks; our ability to maintain

relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; the potential for actual claims to exceed our estimates related to

expected medical claims; our ability to develop and maintain satisfactory relationships with health care payors, physicians, hospitals, other health service providers and with producers and consultants; potential liability in connection with managing

medical practices and operating pharmacies, onsite clinics and other types of medical facilities; uncertainties surrounding participation in government-sponsored programs and providing services to payors who participate in government-sponsored

programs; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; compliance with applicable privacy, security and data laws, regulations and

standards; the outcome of litigation, regulatory audits and investigations; compliance costs and potential failure of our prevention, detection and control systems; our ability to invest in and properly maintain our information technology and other

business systems; our ability to prevent or contain effects of a potential cyberattack or other privacy or data security incident; risks related to our use of artificial intelligence and machine learning; dependence on success of relationships with

third parties; risk of significant disruption within our operations or among key suppliers or third parties; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency

exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations which could lead to an impairment

charge; our ability to achieve our strategic and operational initiatives; unfavorable economic and market conditions, the risk of a recession or other economic downturn and resulting impact on employment metrics, stock market or changes in interest

rates; risks related to a downgrade in financial strength ratings of our insurance subsidiaries; the impact of our significant indebtedness and the potential for further indebtedness in the future; credit risk related to our reinsurers; as well as

more specific risks and uncertainties discussed in our most recent report on Form 10-K and subsequent reports on Forms 10-Q and 8-K available through the Investor Relations section of www.thecignagroup.com. You should not place undue reliance on

forward-looking statements, which speak only as of the date they are made, are not guarantees of future performance or results, and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. The Cigna Group

undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by law.

THE CIGNA GROUP

Exhibit 1

COMPARATIVE SUMMARY OF FINANCIAL RESULTS (unaudited)

Three Months Ended

Six Months Ended

Three Months

Ended

June 30,

March 31,

(Dollars in millions, except per share amounts)

2026

2025

2026

2025

2026

REVENUES

Pharmacy revenues

57,172

53,649

111,209

102,282

54,037

Premiums

9,859

9,156

19,671

21,892

9,812

Fees and other revenues

4,365

4,137

8,808

8,032

4,443

Net investment income

272

236

474

202

Total revenues

71,668

67,178

140,162

132,680

68,494

Net investment results from certain equity method investments

(110

)

(44

)

(87

)

(94

)

Adjusted revenues (1)

71,558

67,134

140,075

132,586

68,517

Shareholders’ net income

1,660

1,532

3,314

2,855

1,654

Pre-tax adjusted income (loss) from operations by segment

Evernorth Health Services

1,663

1,696

3,129

3,130

1,466

Cigna Healthcare

1,276

1,094

2,790

2,381

1,514

Corporate and Other Operations

(389

)

(357

)

(766

)

(768

)

(377

)

Adjusted income tax expense

(496

)

(503

)

(1,041

)

(973

)

(545

)

Consolidated after-tax adjusted income from operations

2,054

1,930

4,112

3,770

2,058

Weighted average shares (in thousands)

263,962

268,154

263,990

270,540

264,017

Common shares outstanding (in thousands)

264,154

266,901

264,498

SHAREHOLDERS’ EQUITY at June 30,

42,620

40,214

SHAREHOLDERS’ EQUITY PER SHARE at June 30,

161.35

150.67

Three Months Ended

Six Months Ended

Three Months Ended

June 30,

March 31,

2026

2025

2026

2025

2026

(Dollars in millions, except per share amounts)

Pre-tax

After-tax

Pre-tax

After-tax

Pre-tax

After-tax

Pre-tax

After-tax

Pre-tax

After-tax

SHAREHOLDERS’ NET INCOME

Shareholders’ net income

1,660

1,532

3,314

2,855

1,654

Adjustments to reconcile to adjusted income from operations

Net investment (gains) (2)

(41

)

(55

)

(96

)

(103

)

(276

)

(288

)

(144

)

(151

)

(235

)

(233

)

Amortization of acquired intangible assets

389

296

422

330

779

611

844

666

390

315

Special Items

Strategic optimization program

129

450

343

344

261

380

290

Integration and transaction-related costs

290

220

Charges (benefits) associated with litigation matters

—

(11

)

Deferred tax expenses, net

—

(Gain) on sale of businesses

)

—

)

(41

)

(115

)

—

)

Adjusted income from operations (3)

2,054

1,930

4,112

3,770

2,058

DILUTED EARNINGS PER SHARE

Shareholders’ net income

6.29

5.71

12.55

10.55

6.26

Adjustments to reconcile to adjusted income from operations

Net investment (gains) (2)

(0.16

)

(0.21

)

(0.36

)

(0.38

)

(1.05

)

(1.09

)

(0.53

)

(0.56

)

(0.89

)

(0.88

)

Amortization of acquired intangible assets

1.48

1.12

1.57

1.23

2.96

2.32

3.12

2.47

1.48

1.19

Special Items

Strategic optimization program

0.27

0.20

0.48

0.37

1.70

1.29

1.27

0.97

1.44

1.10

Integration and transaction-related costs

0.13

0.10

0.28

0.21

0.26

0.20

1.07

0.81

0.13

0.10

Charges (benefits) associated with litigation matters

0.28

0.23

—

0.25

0.20

—

(0.04

)

(0.03

)

Deferred tax expenses, net

—

0.06

—

0.06

—

0.13

—

0.13

—

0.06

(Gain) on sale of businesses

(0.02

)

(0.01

)

—

(0.02

)

(0.02

)

(0.15

)

(0.43

)

—

(0.01

)

Adjusted income from operations (3)

7.78

7.20

15.58

13.94

7.79

(1) Adjusted revenues is defined as total revenues excluding the following

adjustments: special items and The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. These items are excluded because they are not indicative of

past or future underlying performance of our businesses.

(2) Includes Net investment gains/losses as presented in our Consolidated Statements

of Income, as well as the Company’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated

Statements of Income.

(3) Adjusted income (loss) from operations is defined as shareholders’ net income

(or income before income taxes less pre-tax income (loss) attributable to noncontrolling interests for the segment metric) excluding the following adjustments: net investment gains/losses, amortization of acquired intangible assets and special

items. The Cigna Group’s share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded.

GRAPHIC

Filename: image00001.jpg · Sequence: 6

Binary file (5058 bytes)

Download image00001.jpg

GRAPHIC

Filename: image00002.jpg · Sequence: 7

Binary file (3872 bytes)

Download image00002.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Document and Entity Information

Jul. 30, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 30, 2026

Entity File Number

001-38769

Entity Registrant Name

The Cigna Group

Entity Central Index Key

0001739940

Entity Incorporation, State or Country Code

Entity Tax Identification Number

82-4991898

Entity Address, Address Line One

900 Cottage Grove Road

Entity Address, City or Town

Bloomfield

Entity Address, State or Province

Entity Address, Postal Zip Code

06002

City Area Code

860

Local Phone Number

226-6000

Title of 12(b) Security

Common Stock, Par Value $0.01

Trading Symbol

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration